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Background: Endocrine therapy (ET) is the mainstay of treatment for hormone receptor-
positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast
cancer; however, adaptive mechanisms emerge in about 25–30% of cases through
alterations in the estrogen receptor ligand-binding domain, with a consequent ligand-
independent estrogen receptor activity. Epigenetic-mediated events are less known
and potentially involved in alternative mechanisms of resistance. The aim of this study
was to test the feasibility of estrogen receptor 1 (ESR1) epigenetic characterization
through liquid biopsy and to show its potential longitudinal application for an early ET
sensitivity assessment.
Methods: A cohort of 49 women with hormone receptor-positive HER2-negative
MBC was prospectively enrolled and characterized through circulating tumor DNA
using methylation-specific droplet digital PCR (MS-ddPCR) before treatment start (BL)
and after 3 months concomitantly with computed tomography (CT) scan restaging
(EV1). ESR1 epigenetic status was defined by assessing the methylation of its main
promoters (promA and promB). The most established cell-free tumor DNA (ctDNA)
factors associated with ET resistance [ESR1 and phosphatidylinositol-4,5-bisphosphate
3-kinase, catalytic subunit alpha (PIK3CA) mutations] were assessed through next-
generation sequencing. Associations were tested through Mann–Whitney U test,
matched pairs variations through Wilcoxon signed rank test, and survival was analyzed
by log-rank test.
Results: The ET backbone was mainly based on aromatase inhibitors (AIs) (70.83%)
in association with CDK4/6 inhibitors (93.75%). Significantly lower promA levels at
baseline were observed in patients with liver metastases (P = 0.0212) and in patients
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with ESR1 mutations (P = 0.0091). No significant impact on PFS was observed for
promA (P = 0.3777) and promB (P = 0.7455) dichotomized at the median while a ≥2-
fold increase in promB or in either promA or promB at EV1 resulted in a significantly
worse prognosis (respectively P = 0.0189, P = 0.0294). A significant increase at EV1
was observed for promB among patients with PIK3CA mutation (P = 0.0173). A trend
was observed for promB in ESR1 wild-type patients and for promA in the ESR1
mutant subgroup.
Conclusion: The study proofed the concept of an epigenetic characterization strategy
based on ctDNA and is capable of being integrated in the current clinical workflow to
give useful insights on treatment sensitivity.
Keywords: circulating tumor DNA, DNA methylation, endocrine treatment, ESR1, liquid biopsy
BACKGROUND
Breast cancer (BC) is a complex disease encompassing clinically
and molecularly heterogeneous tumors. Approximately 70% of
BC express hormone receptors and are, therefore, eligible for
endocrine treatment (ET). In the last decades, several ETs have
been introduced in the management of hormone receptor-
positive human epidermal growth factor receptor 2 (HER2)-
negative (luminal-like) BC, including aromatase inhibitors
(AIs), selective estrogen receptor modulators (SERM), and
degraders (SERD), that dramatically decreased mortality (1–3).
Despite that, about 25–30% of metastatic BC (MBC) previously
treated with ET develop resistance due to alterations in the
estrogen receptor (ER) ligand-binding domain, showing a ligand-
independent ER activity and in particular, up to 20% develop
mutations in the ER gene (ESR1) (4–7). Although the main
known ET resistance mechanisms rely on the mutations of few
genes, they account only for 40% of cases, as genetic-mediated
events are not the only mechanisms capable to perturbate ESR1
activity and expression (8, 9). Despite being initially neglected,
ESR1 mutations are currently one of the main known ET
resistance factors in luminal-like MBC. As a matter of fact,
ESR1 mutations are not often present in primary tumors but
are rather selected during AI-based therapies and eventually
characterize the dominant clone when disease progression occurs
(10). Moreover, their onset is associated with a lower treatment
benefit in subsequent lines when an AI-based backbone is
selected, while discordant data are available with respect to
SERDS (5, 11). DNA methylation, an epigenetic phenomenon,
leads to gene silencing through the addition of a methyl group
to the fifth carbon of the cytosine residue in the context of GcP
islands (CGIs) and cis-regulatory elements (CREs), as promoter
and enhancer regions (12–15). In luminal-like MBC, the ESR1
promoter methylation drives the silencing of ESR1, with a loss
of ER tissue expression and consequent ET resistance (16).
ESR1 is located in an extremely complex locus of 450 kb in
chromosome 6q25.1 and its expression is regulated by several
promoters. The different transcripts generated by each promoter
show a unique 5’-untranslated region, and they are subject to
splicing to form a single mRNA (17). Several promoters are
involved in ESR1’s tissue-specific regulation and in particular,
two proximal promoters (promoter A and B) are located within
∼2 kb of the transcription start site and are transcriptionally
active in BC (18–20).
Liquid biopsy, based on the analysis of circulating cell-free
tumor DNA (ctDNA) and circulating tumor cells (CTCs),
is gaining momentum as a noninvasive real-time tumor-
monitoring tool that may reflect tumor biology and evolution.
This concept was explored by analyzing the most established
ET resistance factors, ESR1 and phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)
mutations, in the PALOMA-3 study. While it has been
highlighted that a relative change in PIK3CA allele frequency
after 15 days strongly predicted PFS on palbociclib and
fulvestrant, on the other hand, ESR1 dynamics offered limited
information on the long-term clinical outcome, probably due to
early divergent response of tumor subclones to treatment and
the more gradual onset of new ESR1 mutations (21). On the
other hand, few studies have proved the association between ET
sensitivity and ESR1 promoter methylation (22).
The aim of this study was to test the feasibility of
ESR1 epigenetic characterization through liquid biopsy and to
show its potential longitudinal application for an early ET
sensitivity assessment.
MATERIALS AND METHODS
Study Population and Ethics Statement
A cohort of 49 women with luminal-like MBC was prospectively
enrolled in the CRO-2018-56 multicenter pragmatic study,
between 2018 and 2019. All patients were diagnosed with
luminal-like MBC and received either fulvestrant or AIs with
or without CDK4/6 inhibitors as first-line ET according to the
investigator’s choice. Diagnosis of any secondary malignancy
within the last 3 years and prior ET for MBC were the two
main exclusion criteria. Patients could have received both ET and
chemotherapy in the adjuvant and neoadjuvant setting. Samples
were collected before treatment start [baseline (BL)] and after
3 months concomitantly with computed tomography (CT) scan
restaging [first evaluation (EV1)]. The study was approved by the
ethics committee under the CEUR-2018-Sper-056-CRO protocol.
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Extraction of Circulating Tumor DNA
From Plasma Samples
Blood samples were collected using the PAXgene Blood ccfDNA
Tubes (Qiagen) or the Cell-Free DNA BCT tubes (Streck). Plasma
was then recovered and stored at −80◦C. ctDNA was isolated
from 4.8 ml aliquots of plasma with the QIAsymphony PAXgene
Blood ccfDNA Kit (Qiagen) through the QIAsymphony SP
instrument (Qiagen) using the recommended Standard Protocol
Line (STA) for small fragment enrichment and eluted in 60 µl
of elution buffer (Qiagen). ctDNA concentration was estimated
using the Qubit 1X dsDNA HS Assay Kit (Qiagen).
Next-Generation Sequencing
Primers (Sigma) were designed to amplify the regions of the
genes that contained hotspot mutation and were built with
different 5′-adapter region. To prepare the next-generation
sequencing (NGS) library, we carried out two consecutive rounds
of PCR, both of which used Phusion Hot Start II High-
Fidelity DNA Polymerase (Thermo Fisher). In the first round,
primers recognized and amplified the region(s) of interest,
and in the second one, PCR products from first round were
diluted 1:100 and then amplified with Index primers (IDT) that
barcoded each sample for subsequent univocal identification.
After amplification, Wizard R© SV Gel and PCR Clean-Up System
(Promega) were used to purify the fragments, following the
manufacturer’s instructions. Finally, all samples were diluted
to a final concentration of 2 nM, to create the library. Phix
sequencing Control (Illumina) was added and the library was
finally denatured and loaded into the cartridge (Illumina).
Sequencing data were exported as BAM and VCF files and
analyzed using the IGV software and the VariantStudio software
(Illumina), respectively (Supplementary Data Sheet 1). After
quality check controls and filtering, reads and variants distributed
in target regions were analyzed and annotated.
Methylation-Specific Droplet Digital PCR
CpG island prediction and primer/probe design were assessed
on the Methprimer 2.0 online platform according to standard
recommendations (23). Probes’ sequences included at least three
potential methylation sites, and probe-specific binding sites
included several cytosines, ensuring specificity for converted
DNA. No CpG were included in primer pairs to enforce
methylation-independent primer efficiencies. The amplicon size
was kept on 100 bp or less, to efficiently anneal on ctDNA
fragments. Two probes were designed: one was labeled in 6-FAM
and was specific for methylated DNA and the other was labeled
in HEX specific for un-methylated DNA.
The EZ DNA Methylation-GoldTM Kit (Zymo Research)
was used for bisulfite conversion of 10 ng ctDNA, according
to the manufacturer’s standard protocol. Bisulfite-converted
ctDNA was eluted in 20 µl elution buffer for downstream
analysis. Ten nanograms of Human WGA Methylated and Non-
methylated DNA Sets (Zymo Research) were bisulfite converted
and processed with each droplet digital PCR (ddPCR) experiment
as positive and negative controls.
Five microliters of bisulfite-converted ctDNA were then used
for absolute quantification of ESR1 promoter methylation levels.
Samples were considered positive for methylation when at
least three positive droplets were evaluated. The total number
of copies/reactions was assessed, and methylation levels were
expressed as fractional abundance of methylated DNA alleles
[beta value (β)]. Samples were run in duplicated and then merged
for further analysis. Droplets were generated on the automated
droplet generator QX200 AutoDGTM (Bio-Rad), and after PCR
amplification, droplets were read on the QX200TM Droplet
Reader (Bio-Rad). Data were analyzed using the QuantaSoftTM
1.7.4 Software (Bio-Rad).
Statistical Analysis
Clinico-pathological characteristics were summarized through
descriptive analysis. Categorical variables were described through
frequency distribution, whereas continuous variables were
reported through median and interquartile range (IQR). The
BL staging was performed concomitantly to liquid biopsy.
Distant localizations were categorized based on the presence of
specific organ involvement (e.g., liver involvement, yes vs. no)
independently from other metastatic sites.
Associations between promoter methylation, clinico-
pathological characteristics, and detectable mutations were
explored through Mann–Whitney U test. The association
between metastatic sites and median level of promA/B was
investigated through uni- and multivariate logistic regression.
Matched pairs variations across BL and EV1 were tested through
Wilcoxon signed rank test.
Progression-free survival (PFS) was defined as the time from
study enrollment to disease progression (according to RECIST
criteria) or death from any cause or date of last follow-up,
while overall survival (OS) was defined as the time from study
enrollment to death from any cause. Censoring was applied to
patients without an endpoint event at the last follow-up visit.
Survival was represented by Kaplan-Meier estimator plot and
analyzed by log-rank test. The differential prognostic impact of
promA/B across clinically relevant subgroups was tested by Cox
regression and represented though forest plot.
All P-values were two sided, with P < 0.05 considered the
threshold for statistical significance.
Statistical analysis was conducted using the StataCorp 2016
Stata Statistical Software: Release 15.1 (College Station, TX,
United States), R (The R foundation for Statistical Computing.
version 3.3.1) (2016-06-21), and JMP (SAS Institute, version 14).
RESULTS
A cohort of 49 patients with luminal-like MBC treated with
first-line ET was prospectively enrolled between May 2018 and
November 2019. One patient rapidly progressed during the
induction of ovarian suppression and was therefore not eligible
for the analysis at EV1. The first-line ET backbone was mainly
based on AIs (70.83%) in association with CDK4/6 inhibitors
(93.75%). Of the 11 patients treated with a fulvestrant-based ET, 9
patients relapsed during adjuvant ET. Among them, five relapsed
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during the extended adjuvant phased (i.e., after more than 5 years
of adjuvant treatment).
Consistently with literature, bone metastases were the
most represented (Table 1) (24, 25). Median follow-up was
11.9 months (IQR, 10.1–19.3).
ESR1 and PIK3CA mutations are currently the most
established ctDNA factors associated with ET resistance and were
therefore assessed through an amplicon-based NGS panel for a
more complete baseline characterization.
TABLE 1 | Clinico-pathological characteristics of the study cohort.
Median IQR
Age (years) 63 52–71
ER (%) 95 90–95






Wild type 40 82
Mutated 7 14
Not evaluable 2 4
PIK3CA status
Wild type 36 72
Mutated 11 22




















AI single agent 1 2
Fulvestrant single agent 2 4
AI and CDK4/6i 34 71
Fulvestrant and CDK4/6i 11 23
IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; ESR1,
estrogen receptor 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha.
ESR1 and PIK3CA were mutated in 7 (14%) and 11 (23%)
patients, respectively. ESR1 variants were Y537S (3/7, 44%),
Y537N (1/7, 14%), H377R (1/7, 14%), and D538G (2/7, 28%),
while PIK3CA variants were H1047R (8/11, 73%), E545K (2/11,
18%), and H1047L (1/11, 9%). Full details are available in
Supplementary Table 1.
The median methylation at BL for promoter A (promA) was
0.39 (IQR, 0.33–0.43) and 0.33 (IQR, 0.22–0.46) for promB, with
no significant differences in the overall population (P = 0.1127)
(Figure 1A). At EV1, promA and promB medians were,
respectively, 0.47 (IQR, 0.33–0.60) and 0.40 (IQR, 0.33–0.50) at
EV1 (P = 0.0639) (Figure 1B). No direct correlation was observed
after Shapiro–Wilk normality testing at BL (R2 = 0.0978)
and EV1 (R2 = 0.0265).
Baseline promA Varied Across Baseline
Characteristics and Was Not Associated
With Prognosis
Promoter A and B were investigated at BL to explore potential
factors associated with ESR1’s epigenetic status (Table 2). No
differences were observed with respect to age, while significantly
lower promA levels were observed in patients with liver
metastases (P = 0.011). No significant variations were observed
across all investigated sites for promB, numerically higher promB
levels were detected in patients with soft tissue involvement
(Table 2). PromA was significantly lower in patients with ESR1
mutations (median, 0.41; IQR, 0.33–0.46; median, 0.25; IQR, 0.19
0.35, respectively, in ESR1 wild-type and mutated; P = 0.0091)
(Figure 2A). No associations were observed with respect to
PIK3CA mutational status (Figure 2).
The association between metastatic sites and promA/B was
further explored through multivariate logistic regression after
dichotomization at the median value. The inverse association
between promA and liver involvement was confirmed (OR = 0.09;
95% CI = 0.01–0.58; P = 0.0109) (Table 3).
In this subgroup, median ER expression of the most
updated biopsy was 90% (range, 30–100%) while the median
ER expression was 95% (range, 80–100%) in patients without
liver involvement.
The prognostic impact of promA and promB was then
explored in terms of PFS and OS. At BL, no significant impact was
observed for promA and promB dichotomized at the median for
both PFS (respectively P = 0.1702 and P = 0.1322) (Figures 3A,B)
and OS (respectively P = 0.7244 and P = 0.4467) (Figures 3C,D).
The Longitudinal Evaluation of prom A/B
Is Feasible and Can Give Insights on
Treatment Sensitivity
Promoter A and B were then assessed at EV1 (Figure 1B). Only
numerical variations were observed from BL to EV1 for promA
and promB after normalization on the BL values (respectively
P = 0.0788 and P = 0.0857), notably two cases showed a 15- and
18-fold increase in promB levels (Figures 4A,B).
The impact of a variation in promA and promB between
BL and EV1 was investigated both in terms of PFS and
OS. To exclude possible biasses derived from the biological
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FIGURE 1 | Overall distribution of ESR1 promoter A (promA, purple) and B (promB, blue) methylation at baseline (A) and at first CT scan evaluation after 3 months of
ET (B). Median methylation at baseline was 0.39 for promA and 0.33 for promB (P = 0.1127) (A). At first CT scan evaluation after 3 months of ET median methylation
was 0.47 for promA and 0.40 for promB (P = 0.0639) (B).
TABLE 2 | Distribution of promoter A and B methylation levels (promA and promB)
across age groups and metastatic sites.
promA promB
Median IQR P Median IQR P
Age
<50 39 28–44.25 0.7213 32 21–50 0.8304
≥50 38.5 33–46.5 33 21.8–46
Liver involvement
No 41.5 34.5–50 0.0196 33.75 21–48.5 0.5009
Yes 36.5 25–38.5 28 23.3–42
Lung involvement
No 41.3 33.8–48.3 0.1498 32 21–45 0.2486
Yes 36.5 30.5–40.5 40 24–50
Bone involvement
No 41.5 36.5–46 0.1268 37.3 30.8–50 0.1017
Yes 38.5 31–41.5 26.8 20.3–44
Lymph nodes
involvement
No 38.5 33–43.5 0.9625 32 21–42.5 0.2150
Yes 39.5 31–48.5 37.5 24–50
Soft tissue
involvement
No 40.5 33–46.5 0.1137 32 21–42.8 0.0688
Yes 31 30.5–35.5 50 38.3–55
Methylation levels were significantly lower for promA in patients with liver
involvement (P = 0.0196). Significance was tested through the Mann–Whitney
U test.
meaning of undetectable ctDNA levels, only patents with
detectable methylation at BL and EV1 were included in this
analysis (26).
While promA doubling alone has no impact on PFS
nor OS (Figures 4C,E), a ≥2-fold increase in promB
resulted in a significantly worse prognosis both in terms
of PFS and OS (respectively P = 0.0136 and P = 0.0400)
(Figure 4D,F). The prognostic impact of a 2-fold increase
in promB was explored across clinically relevant subgroups.
In the total population, hazard ratio (HR) was 3.47
(95% CI, 1.20–10.04; P = 0.0214), consistent results
were observed according to visceral involvement, first-
line ET backbone, and ESR1 and PIK3CA mutational
status (Figure 4G).
The prognostic impact of a 2-fold increase of either
promA or promB was moreover investigated. A ≥2-fold
increase in either promA or promB was associated to a
significantly worse prognosis in terms of PFS (P = 0.0338)
(Figures 5A,B) that was consistent across all considered
subgroups (Figure 5C).
Given the established role of ESR1 and PIK3CA gene
mutations in ET resistance, promA and promB variations
were investigated according to ESR1 and PIK3CA mutational
status (Figure 6). A significant increase was observed for
promB among patients with PIK3CA mutation (P = 0.0173)
(Figure 6H). A trend was observed for promA in the ESR1
mutant subgroup (Figure 4B) and for promB in ESR1 wild-type
patients (Figure 6C).
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FIGURE 2 | Promoter A and B methylation (promA and promB) according to ESR1 and PIK3CA mutational status. PromA methylation levels were lower in patients
with a ctDNA-detectable ESR1 mutation (A). No associations were observed with respect to PIK3CA mutational status or in ESR1 wild type patients (B–D).
TABLE 3 | A significantly lower promA was confirmed in patients with liver
involvement after correction for the most represented metastatic sites
(P = 0.0109).
promA promA
OR 95% Cl P OR 95% Cl P
Liver involvement
No 1 0.0109 1 0.1745
Yes 0.09 0.01–0.58 0.34 0.07–1.61
Lung involvement
No 1 0.0635 1 0.7761
Yes 0.14 0.02–1.12 1.28 0.23–7.06
Bone involvement
No 1 0.1118 1 0.1711
Yes 0.28 0.06–1.35 0.33 0.07–1.61
Lymph nodes
involvement
No 1 0.0806 1 0.3078
Yes 5.40 0.81–35.80 2.43 0.44–13.44
Significance was tested through multivariate logistic regression, promA and B were
dichotomized at median.
DISCUSSION
De novo and acquired ET resistance result in cancer progression
and metastatic spreading, limiting clinical benefit in luminal-like
MBC. Mutations of the ESR1 gene have been described in 20% of
ET-resistant cases and represents one of the main ET resistance
mechanisms, but the relationship between epigenetic events and
treatment-induced resistance is still unclear (10, 27–30).
The present study tested the feasibility of evaluating
ESR1 CRE hypermethylation in liquid biopsies from luminal-
like MBC and explored the potential impact on prognosis
of its dynamics.
The most transcriptionally active ESR1 promoters (promoter
A and B) were analyzed at baseline and after 3 months of
ET. No significant cross-associations were observed between
the two, suggesting their independent role and potential
for mutual integration. The baseline levels of promA were
associated with metastatic liver involvement, which was
confirmed also on multivariate analysis. Uncovering the
link between metastatic behavior and tumor biology is an
unmet clinical need as it can potentially enable a more
granular prognostic stratification and guide disease monitoring
strategies by suggesting the best imaging technique for each
patient (25, 31–33).
The prognostic role of promA and promB was moreover
explored. Although no prognostic impact was observed for
both BL promA and promB, a 2-fold increase in promB
and in either promA and promB after 3 months of ET
was associated with a worse PFS and OS. Notably, PFS
results were consistent across clinically relevant subgroups, such
as ET backbone and ESR1 and PIK3CA mutational status.
Although preliminary, these results may suggest the added
value of longitudinal genetic and epigenetic monitoring as the
prognostic role of ESR1-associated features is likely the result
of a complex interplay between inherit biological features and
acquired resistance mechanisms induced by ET, rather than a
baseline characteristic.
A similar scenario was described by the preliminary results
of the PADA-1 study which explored the impact of baseline
ESR1 mutation and its dynamics on PFS. Out of the 32
analyzed patients, 25 (78%) had an ESR1 mutation that became
undetectable in ctDNA within the first 5 months of ET. Although
14 patients had a recurrence of ESR1 mutation with a consequent
progression, 9 patients (36%) were still free from ESR1 mutation
and progression at the time of analysis. Intriguingly, 2 patients
(8%) experienced a progression without the recurrence of
ESR1 mutation. Since the study was based on a genetic-only
characterization, these results suggest the need for a wider,
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FIGURE 3 | Impact on PFS and OS of promA (purple) (A,C) and promB (blue) (B,D). No significant impact was observed for promA and promB dichotomized at the
median for both PFS (respectively P = 0.1702 and P = 0.1322) (A,B) and OS (respectively P = 0.7244 and P = 0.4467) (C,D).
genetic, and epigenetic characterization to better characterize the
complexity of ET resistance (34).
It has previously been shown that ESR1 promoter methylation
was significantly associated with either ER-negative early BC or
with a heterogenous ER expression in the luminal-like disease
(27). This suggested that silencing by methylation could affect
the expression of ER and in turn treatment response, although
without evidence of a survival impact (27).
Endocrine-resistant cells are characterized by a distinctive
DNA methylome. Moreover, hypermethylation can affect
estrogen-regulated enhancers resulting in a reduced ESR1
binding with a consequent decreased gene expression of key
effectors of ESR1 activity (12). Furthermore, ESR1-responsive
enhancer hypomethylation is critical in the transition from
normal epithelial cells to endocrine-responsive luminal-like BC,
supporting the concept that dynamic epigenetic variations are
pivotal in cancer evolution (12).
Notwithstanding the preliminary follow-up and sample size,
our results suggest that the combination of promA and promB
dynamics could be more informative than the ESR1 mutational
status alone, since epigenetic modifications have a faster onset
and could realistically be able to grasp features linked to an
inherently lower sensitivity to ET (10, 28–30).
The added value of a longitudinal strategy is also supported by
the lack of impact on PFS of baseline promA and promB. If on
one hand mutational alterations of ESR1 are late events mainly
induced by therapy and often maintained across the subsequent
lines, on the other, epigenetic alterations are highly dynamic and
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FIGURE 4 | Variation of promA (purple) and promB (blue) between BL and EV1 (A,B) and impact on PFS (C,D) and OS (E,F) of a ≥2-fold increase in promA and
promB. Subgroup analysis of the impact on PFS of a ≥2-fold increase in promB (G). A numerical increase in promA was observed after normalization to the baseline
levels. For two cases, an 18- and 15-fold increase in promB was observed (B) and were, therefore, out of scale (B). A ≥2-fold increase in promA was not associated
with PFS or OS (C,E), while a doubling in promB resulted in a significantly worse prognosis both on PFS and OS (D,F). Notably, subgroup analysis showed a
consistent impact on PFS across different ET backbones and according to ESR1 and PIK3CA mutational status.
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FIGURE 5 | Impact on PFS (A) and OS (B) and subgroup analysis in terms of PFS (C) of a ≥2-fold increase in either promA or promB. A ≥2-fold increase in promA
or promB was associated with an impact on PFS (A). Subgroup analysis showed a consistent impact on PFS across different ET backbones and according to ESR1
and PIK3CA mutational status (C).
reflect the actual real-time changes caused by ET at the moment
of the blood draw.
Alternative approaches for a more comprehensive liquid
biopsy-based characterization of luminal-like MBC were initially
focused on CTCs. A previously reported pilot study based
on 17 patients after progression to ET (respectively 7 treated
with fulvestrant and 10 with AI) highlighted an association
between ET resistance and both enumeration and heterogeneous
Frontiers in Oncology | www.frontiersin.org 9 September 2020 | Volume 10 | Article 550185
fonc-10-550185 September 17, 2020 Time: 18:53 # 10
Gerratana et al. ctDNA Epigenetic Characterization of MBC
FIGURE 6 | Promoter A (purple) and B (blue) variations between BL and EV1 according to ESR1 and PIK3CA mutational status. A significant increase was observed
for promB in PIK3CA-mutated patients (H). A numerical difference was observed for promA in the ESR1-mutated subgroup (B) and promB in ESR1 wild-type MBC
(C). No significant promA variations were observed in ESR1 wild-type patients (A) or with respect to PIK3CA mutational status (E,F). No significant promB variations
were observed in ESR1-mutated or in PIK3CA wild-type patients (D,G).
ER expression of CTCs (35). Notably, all patients treated
with AI showed a heterogeneous ER expression in CTCs,
while two patients treated with fulvestrant had no detectable
CTC expression of ER and three had heterogeneous CTC ER,
probably due to an incomplete degradation of the ER target by
fulvestrant (35). A larger study characterized 122 MBC patients
through a methylation-specific (MS) qPCR assay applied to
CTCs and, in a smaller subgroup (58 patients), in matched
plasma samples. ESR1 methylation was observed in 10 out
of 36 CTC-positive samples (27.8%), was highly concordant
with the paired ctDNA samples, and was moreover associated
with a lack of response to everolimus and exemestane (22).
These results, although supporting the concept of integrated
genetic and epigenetic events concurring to ET resistance,
are on the other hand limited to patients defined as Stage
IVaggressive through the CellSearch platform (i.e., with ≥5
CTCs/7 ml of blood), a population limited to 45% of the
overall MBC patients and up to 49% in the luminal-like
subgroup (36).
A ctDNA approach, on the other hand, can be applied
to a broader cohort of patients also thanks to the higher
sensitivity of ddPCR.
In our cohort, ESR1 and PIK3CA mutations were detected,
respectively in 14 and 23% of patients and, intriguingly, a
significantly lower promA was highlighted in patients with
ESR1 mutation.
ESR1 is often affected by activating mutations, such as Y537
and D538 (located in the helix 12 of ESR1 ligand binding
domain), which result in an agonist form of ESR1 (28). Given
these premises, it is mechanistically tempting to think that
promoter methylation could represent a detrimental event to
an acquired resistance advantage and that the latter could be
hindered by epigenetic silencing.
Although intriguing and prospectively generated, these
results may have some limitations. If on one hand the
proof of concept study enrolled a homogeneous cohort of
luminal MBC patients treated with first-line ET and was
therefore an appropriate basis for hypothesis generation and
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for testing the technological transferability of longitudinal
epigenetic characterization, on the other hand, the sample size
is limited and hinders a deeper characterization of subgroups
of particular interest. Consistently, the median follow-up is
limited and may underestimate the real prognostic impact of
the analyzed biomarkers. Moreover, additional timepoints could
increase promA and promB curve’s resolution and therefore
provide precious information for optimal timing definition.
CONCLUSION
The present study proofed the concept that an epigenetic
characterization strategy based on ctDNA can be integrated
in the current clinical workflow of patients with metastatic
breast cancer to give useful insights on treatment sensitivity.
Although exploratory, these results support the emerging new
concept of a dynamic epigenetic profiling. Based on these
data, a cohort expansion is planned to validate and further
develop this approach.
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